Advertisement

Topics

Latest "Odonate Therapeutics, Inc." News Stories

02:30 EDT 24th May 2018 | BioPortfolio

Here are the most relevant search results for "Odonate Therapeutics, Inc." found in our extensive news archives from over 250 global news sources.

More Information about Odonate Therapeutics, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Odonate Therapeutics, Inc. for you to read. Along with our medical data and news we also list Odonate Therapeutics, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Odonate Therapeutics, Inc. Companies for you to search.

Showing "Odonate Therapeutics" News Articles 1–25 of 6,400+

Wednesday 23rd May 2018

Arcturus Therapeutics Comments on Court Ruling on Undisclosed Group Organized by Joseph E. Payne and his Associates in Violation of Regulation 13D

California Federal Court Rules that Arcturus is Likely to Succeed on Merits of its Claims Against Payne Further Violations by Payne and His Associates Enjoined to Permit all Arcturus Shareholders to Have a Fully Informed Vote at Upcoming Extraordinary Shareholders Meeting SAN DIEGO, May 23, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, to...


BCell Activating Factor BAFF Inhibitor Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1250

BCell Activating Factor BAFF Inhibitor Pipeline Insight, 2018 report by DelveInsight offers comprehensive insights of the pipeline under development therapeutics scenario and growth prospects across BCell Activating Factor BAFF Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with comple...

Crescita’s US Prescription Product is “Launching Shortly,” says CEO

Crescita Therapeutics' new U.S. launch through its partner, Taro Pharmaceuticals of Pliaglis is just one of the many global expansions the company is expecting in the coming years. The post Crescita’s US Prescription Product is “Launching Shortly,” says CEO appeared first on Investing News Network.


USC researchers develop new portable device for early-stage malaria detection

According to the World Health Organization, over 216 million people were infected with malaria in 2016, and 445,000 individuals died from the disease. The key to solving this health crisis is early-stage diagnosis when malaria therapeutics are most effective. A new prototype for a portable instrument capable early-stage malaria detection has been developed by a team of researchers at the USC Viter...

Arginine Depletors Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1250

Arginine Depletors Pipeline Insight, 2018 report by DelveInsight offers comprehensive insights of the pipeline under development therapeutics scenario and growth prospects across Arginine Depletors development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental st...

Anika Therapeutics Announces $30 Million Accelerated Share Repurchase

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary

Gilead Sciences to Present at the Jefferies 2018 Healthcare Conference on Wednesday, June 6

Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F. Milligan, PhD, Gilead’s President and Chief Executive Officer; Robin L. Washington, Gilead’s Executive Vice President and Chief Financial Officer; John McHutchison, Gilead’s Chief Scientific Officer and Head of Research & Devel...

Accent Therapeutics launches with $40 million Series A round

Company will pursue RNA-modifying protein targets to discover and develop new treatments in oncology.

rEVO Biologics Inc Strategic SWOT Analysis Review [Report Updated: 22032018] Prices from USD $125

rEVO Biologics Inc Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.This uptotheminute company report will help you to formulate strategies to drive your business ...

Antisense Therapeutics Limited: ATL1103 Phase II Trial Results Published in the European Journal of Endocrinology

MELBOURNE, AUSTRALIA / ACCESSWIRE / May 23, 2018 / Antisense Therapeutics (the "Company" or "ANP") (ASX: ANP; OTC PINK: ATHJF) is pleased to announce the acceptance for publication of previously re...

Cesca Therapeutics’ Chief Technology Officer, Phil Coelho, Provides Deep Dive into the CAR-T Manufacturing Process in Cell & Gene Therapy

Cesca Therapeutics (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Phil Coelho, chief technology officer of the Company’s ThermoGenesis device division, was recently interviewed by Cell & Gene Therapy Insights.  The article, “Driving CAR-T Manufacture Optimization through Technology Innovation,” appear...

G1 Therapeutics (GTHX) Presents At 2018 UBS Global Healthcare Conference - Slideshow

Revance Therapeutics (RVNC) Presents At 2018 UBS Global Healthcare Conference - Slideshow

Neos Therapeutics (NEOS) Presents At 2018 UBS Global Healthcare Conference - Slideshow

BioSensics launches Sensor-Integrated Digital Platform for Clinical Trials

BioSensics LLC, has announced the launch of its Sensor-Integrated Digital Platform for measurement and remote monitoring of movement-based biomarkers in

Five Prime Promotes Bryan Irving to Chief Scientific Officer

Bryan Irving is now executive vice president and chief scientific officer of Five Prime Therapeutics (NASDAQ: FPRX). Irving first joined South San Francisco-based Five Prime last year as vice president of research. His experience also includes posts at CytomX Therapeutics (NASDAQ: CTMX) and Genentech. Clinical-stage Five Prime develops protein therapies to treat cancer and inflammatory […]

Chemotherapy-induced Neutropenia Therapeutics Market - Industry Analysis and Forecast| Technavio

Technavio research analysts have predicted the global chemothera

STAT Plus: Pharmalittle: Insys execs claim feds made ‘ugly insinuations’; just how many Pfizer drugs are in short supply?

Several former Insys Therapeutics defendants derided "inflammatory" charges filed against them by the federal government in a filing that seeks to dismiss the case.

Another Pneumonia Antibiotic is Close to Treating Patients

Nabriva Therapeutics has obtained positive Phase III results for its antibiotic lefamulin and plans to seek FDA approval for the drug by the end of this year. Nabriva Therapeutics has obtained a second round of positive Phase III results for ... The post Another Pneumonia Antibiotic is Close to Treating Patients appeared first on Labiotech.eu.

Landos Biopharma to Participate in Upcoming Digestive Disease Week Conference and BIO International Convention

Landos Biopharma, an emerging biopharmaceutical company focused on developing improved treatments for autoimmune diseases, announced that the company would be participating in

Lundbeck divests two preclinical research programmes to MindImmune Therapeutics

H.Lundbeck, a global pharmaceutical company specialized in psychiatric and neurological disorders, has announced that the company further focuses its preclinical research pipeline with the divestment of two research programmes

Die bewegte Geschichte von Sangamo Therapeutics

Wenn du die Nachrichten in letzter Zeit verfolgt hast, hast du vielleicht von der Genbearbeitung gehört, einem Prozess, bei dem die DNA einer Person neu geschrieben wird, um genetische Störungen zu...

Synedgen Receives FDA 510(k) Clearance for Catasyn™ Advanced Technology Wound Hydrogel

Synedgen, a company leveraging its proprietary glycomics technology platform to develop glycopolymer-based therapeutics for infectious and inflammatory conditions, today announced that it has received 510(k) clearance from the U. S. Food and Drug Administration (FDA) to market its Catasyn™ Advanced Technology Wound Hydrogel both under the direction of a ...

Translate Bio Names John R. Schroer, CFA, Chief Financial Officer

Translate Bio, a leading messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the appointment of John R. Schroer, CFA, as Chief Financial Officer. With 28 years of healthcare investment experience, Mr. Schroer brings expertise in fin...

Vifor Fresenius snap up rights to Cara’s itch therapy

The joint partnership between Vifor Pharma and Fresenius Medical Care, Vifor Fresenius, has put down $50 in upfront cash and an equity investment of $20 million to gain the Ex-US, Japan and South Korea rights to Cara Therapeutics’ Korsuva. Beyond the immediate $70 million investment, the deal is also back loaded with a potential $470 million in regulatory and commercial milestones. read more


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks